MIVACRON Drug Patent Profile

Which patents cover Mivacron, and what generic alternatives are available?

Mivacron is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in MIVACRON is mivacurium chloride. There are two drug master file entries for this compound. Additional details are available on the mivacurium chloride profile page.

Summary for MIVACRON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	5
Patent Applications:	644
Drug Prices:	Drug price information for MIVACRON
DailyMed Link:	MIVACRON at DailyMed

See drug prices for MIVACRON

Recent Clinical Trials for MIVACRON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Université Libre de Bruxelles	N/A
University Hospital Ostrava	N/A
Tang-Du Hospital	Phase 2

See all MIVACRON clinical trials

US Patents and Regulatory Information for MIVACRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	MIVACRON	mivacurium chloride	SOLUTION;INTRAVENOUS	020098-001	Jan 22, 1992		DISCN	Yes	No
Abbvie	MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER	mivacurium chloride	INJECTABLE;INJECTION	020098-002	Jan 22, 1992		DISCN	No	No
Abbvie	MIVACRON	mivacurium chloride	SOLUTION;INTRAVENOUS	020098-004	Jan 22, 1992		DISCN	Yes	No

Expired US Patents for MIVACRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	MIVACRON	mivacurium chloride	SOLUTION;INTRAVENOUS	020098-001	Jan 22, 1992	4,761,418

International Patents for MIVACRON

See the table below for patents covering MIVACRON around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1687	BIS-DIMETHOXYMETHYL(TRIMETHOXYBENZYL)ISOQUINOLINIUM SALTS,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Hungary	T40626
Mexico	9203667	SALES DE BIS-DIMETOXIMETIL (TRIMETOXIBENCIL)QUINOLINO, SU PREPARACION Y COMPOSICINES FARMACEUTICAS QUE LAS CONTIENEN.

Supplementary Protection Certificates for MIVACRON

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0181055	96C0001	Belgium		PRODUCT NAME: MIVACURIUM CHLORID.= MIVACURIUM (+5% OVERDOSERING); NAT REG.: 251 IS 152 F 12 19951114; FIRST REG.: GB 0003/0325 19921208
0181055	SPC/GB93/031	United Kingdom		SPC/GB93/031:, EXPIRES: 20071207

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: MIVACRON

Last updated: July 29, 2025

---

Introduction

MIVACRON, the trade name for the neuromuscular blocker vecuronium bromide, holds a pivotal role within anesthetic procedural protocols worldwide. As an essential agent for facilitating endotracheal intubation and muscle relaxation during surgery, MIVACRON's market performance is shaped by a complex interplay of clinical, regulatory, and economic factors. This analysis delineates the current market landscape, project future financial trends, and examines the drivers that influence MIVACRON's market trajectory.

---

Market Overview

The global neuromuscular blocking agents market, of which MIVACRON is a significant component, was valued at approximately USD 2.5 billion in 2022 with an anticipated compound annual growth rate (CAGR) of around 4.2% through 2030 [1]. MIVACRON’s share within this segment is substantial due to its proven efficacy, safety profile, and widespread approval.

Key regional markets include North America, Europe, Asia-Pacific, Latin America, and the Middle East. North America remains the largest market, driven by advanced healthcare infrastructure, high surgical volumes, and routine perioperative use of neuromuscular blockers. Asia-Pacific demonstrates rapid growth potential owing to increasing healthcare spending, expanding surgical procedures, and rising adoption of modern anesthetic agents.

---

Market Drivers

1. Increasing Surgical Procedures and Anesthesia Use

Growing incidence of surgical interventions, particularly in oncology, cardiovascular, and orthopedic sectors, drives demand for neuromuscular blockers like MIVACRON. The aging global population enhances the necessity for complex surgeries requiring effective muscle relaxation, supporting steady market expansion [2].

2. Technological Advancements

Innovations in anesthetic techniques and drug formulations have bolstered MIVACRON's utility. The development of faster onset and shorter-acting neuromuscular agents improve patient outcomes and operational efficiency, making drugs like MIVACRON favorable.

3. Regulatory Approvals and Guidelines

Established approval from regulatory bodies such as the FDA and EMA ensures market access. Moreover, international anesthesia guidelines endorse the use of MIVACRON for specific surgical contexts, cementing its clinical relevance.

4. Competitive Pricing and Generics

The availability of generic versions has led to cost reductions, expanding access in developing nations and influencing overall market dynamics.

---

Market Challenges

1. Emergence of Alternative Agents

The rise of newer neuromuscular blockers, such as rocuronium and cisatracurium, with rapid onset and reversibility profiles, poses competitive threats to MIVACRON. These agents often offer improved safety margins, influencing clinicians’ selection.

2. Safety and Side Effect Profile

While generally well-tolerated, MIVACRON's adverse effect spectrum, including potential histamine release and cardiovascular instability—though rare—may limit usage in certain patient populations.

3. Supply Chain and Manufacturing Factors

Disruptions, especially during the COVID-19 pandemic, have underscored vulnerabilities in global supply chains, affecting drug availability and pricing.

---

Financial Trajectory and Projections

Current Revenue Trends

MIVACRON's global sales are estimated in the range of USD 850-950 million annually, with North America accounting for approximately 50% of this figure. Europe and Asia-Pacific follow, driven by rising surgical volumes.

Forecasted Growth Dynamics

Projection models suggest a CAGR of 3.8%–4.2% from 2023 through 2030, influenced by:

• Market Penetration of Generics: As patent protections lapse, generic versions will dominate, exerting downward pressure on prices but expanding accessibility.

• Emerging Markets: Rapid healthcare development in emerging economies is expected to drive incremental demand, contributing to overall growth.

• Technological Evolution: Adoption of short-acting, rapid-onset neuromuscular agents may influence MIVACRON’s market share and revenue streams, potentially stabilizing or moderately decreasing it, depending on clinical preferences.

Revenue Optimization Strategies

Pharmaceutical companies may focus on:

• Formulation Improvements: Developing formulations with enhanced safety or reduced dosage requirements.
• Market Expansion: Securing approvals in regulatory bodies in lower-income countries.
• Clinical Education: Promoting evidence-based guidelines for optimized use.

---

Competitive Landscape

Major players in the neuromuscular blocking agents market include Exelon Corporation (Fresenius Kabi), Pfizer, and Aurobindo Pharma. Competitors' strategies, such as price erosion, differentiation through efficacy, or safety, influence MIVACRON's market share.

The entry of biosimilar versions poses both a threat and an opportunity—potentially decreasing prices but also challenging brand loyalty.

---

Regulatory and Patent Considerations

As patent exclusivity periods expire, the market is expected to see heightened generic competition. Patent cliffs are critical inflection points, impacting revenue and incentivizing innovation. Patent filings and extensions remain strategically essential for market incumbents.

---

Conclusion

MIVACRON's market dynamics are driven by expanding surgical volumes, technological advancements, and regional healthcare developments. While emerging alternatives compete for market share, long-standing clinical utility sustains its relevance. The financial trajectory indicates modest yet steady growth, contingent upon regulatory landscapes, competitive pressures, and technological evolution.

---

Key Takeaways

• The global neuromuscular blocker market, including MIVACRON, is poised for slow but steady growth, driven by rising surgical procedures.
• Patent expiration and the proliferation of generics are reshaping pricing and accessibility; strategic positioning around cost and efficacy remains vital.
• Innovations favoring rapid onset and short durations could challenge MIVACRON’s dominance, requiring continual product optimization.
• Emerging markets present significant growth avenues, contingent upon regulatory approvals and healthcare infrastructure development.
• Diversification into novel formulations and active lifecycle management are critical to sustaining revenue streams.

---

FAQs

1. How does MIVACRON compare to newer neuromuscular blockers in clinical efficacy?
MIVACRON offers reliable muscle relaxation with a predictable onset and duration profile. However, newer agents like rocuronium provide faster onset and reversal options, influencing clinician preference based on procedural requirements.

2. What impact will patent expirations have on MIVACRON’s market share?
Patent expiration typically leads to increased generic competition, resulting in price reductions and broader accessibility but may also diminish revenue for brand-name manufacturers.

3. Are there specific regions where MIVACRON’s demand is expected to grow significantly?
Emerging economies in Asia-Pacific and Latin America are expected to exhibit substantial growth owing to expanding surgical volumes and healthcare infrastructure upgrades.

4. What factors could hinder MIVACRON's market expansion?
The advent of superior neuromuscular blockers, safety concerns, and manufacturing/supply chain disruptions could limit growth potential.

5. How are regulators influencing MIVACRON’s market?
Regulatory approvals affirm clinical safety and efficacy; however, post-approval surveillance and guidelines shape prescribing practices, impacting market dynamics.

---

References

[1] MarketsandMarkets. "Neuromuscular Blockers Market by Drug Type, Application, End User – Global Forecast to 2030." 2022.
[2] WHO. "Global Surgery Data and Surgical Care Demand," 2021.